These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 22279517)

  • 1. Molecular chaperones in Parkinson's disease--present and future.
    Ebrahimi-Fakhari D; Wahlster L; McLean PJ
    J Parkinsons Dis; 2011; 1(4):299-320. PubMed ID: 22279517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies.
    Ebrahimi-Fakhari D; Saidi LJ; Wahlster L
    Acta Neuropathol Commun; 2013 Dec; 1(1):79. PubMed ID: 24314025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular chaperones and co-chaperones in Parkinson disease.
    Dimant H; Ebrahimi-Fakhari D; McLean PJ
    Neuroscientist; 2012 Dec; 18(6):589-601. PubMed ID: 22829394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.
    Kalia SK; Kalia LV; McLean PJ
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):741-53. PubMed ID: 20942788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of Parkinson's disease: emerging role of molecular chaperones.
    Bandopadhyay R; de Belleroche J
    Trends Mol Med; 2010 Jan; 16(1):27-36. PubMed ID: 20036196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the Role of Ubiquitin-Proteasome System in Parkinson's Disease.
    Behl T; Kumar S; Althafar ZM; Sehgal A; Singh S; Sharma N; Badavath VN; Yadav S; Bhatia S; Al-Harrasi A; Almoshari Y; Almikhlafi MA; Bungau S
    Mol Neurobiol; 2022 Jul; 59(7):4257-4273. PubMed ID: 35505049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein degradation pathways in Parkinson's disease: curse or blessing.
    Ebrahimi-Fakhari D; Wahlster L; McLean PJ
    Acta Neuropathol; 2012 Aug; 124(2):153-72. PubMed ID: 22744791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of chaperones in Parkinson's disease and prion diseases.
    Winklhofer KF; Tatzelt J
    Handb Exp Pharmacol; 2006; (172):221-58. PubMed ID: 16610362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aggregopathy in neurodegenerative diseases: mechanisms and therapeutic implication.
    Dohm CP; Kermer P; Bähr M
    Neurodegener Dis; 2008; 5(6):321-38. PubMed ID: 18309232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of molecular chaperones in neurodegenerative disorders.
    Meriin AB; Sherman MY
    Int J Hyperthermia; 2005 Aug; 21(5):403-19. PubMed ID: 16048838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein Quality Control by Molecular Chaperones in Neurodegeneration.
    Ciechanover A; Kwon YT
    Front Neurosci; 2017; 11():185. PubMed ID: 28428740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Collective roles of molecular chaperones in protein degradation pathways associated with neurodegenerative diseases.
    Luo GR; Le WD
    Curr Pharm Biotechnol; 2010 Feb; 11(2):180-7. PubMed ID: 20166963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular chaperones and associated cellular clearance mechanisms against toxic protein conformers in Parkinson's disease.
    Hinault MP; Farina-Henriquez-Cuendet A; Goloubinoff P
    Neurodegener Dis; 2011; 8(6):397-412. PubMed ID: 21411979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
    Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
    J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chaperones and Proteostasis: Role in Parkinson's Disease.
    Joshi N; Raveendran A; Nagotu S
    Diseases; 2020 Jun; 8(2):. PubMed ID: 32580484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posttranslational Modifications and Clearing of α-Synuclein Aggregates in Yeast.
    Popova B; Kleinknecht A; Braus GH
    Biomolecules; 2015 Apr; 5(2):617-34. PubMed ID: 25915624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone.
    Lee JS; Kanai K; Suzuki M; Kim WS; Yoo HS; Fu Y; Kim DK; Jung BC; Choi M; Oh KW; Li Y; Nakatani M; Nakazato T; Sekimoto S; Funayama M; Yoshino H; Kubo SI; Nishioka K; Sakai R; Ueyama M; Mochizuki H; Lee HJ; Sardi SP; Halliday GM; Nagai Y; Lee PH; Hattori N; Lee SJ
    Brain; 2019 Sep; 142(9):2845-2859. PubMed ID: 31312839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of molecular chaperone in protein-misfolding brain diseases.
    Wankhede NL; Kale MB; Upaganlawar AB; Taksande BG; Umekar MJ; Behl T; Abdellatif AAH; Bhaskaran PM; Dachani SR; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Dailah HG; Bhatia S; Al-Harrasi A; Bungau S
    Biomed Pharmacother; 2022 Mar; 147():112647. PubMed ID: 35149361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chaperone-Based Therapies for Disease Modification in Parkinson's Disease.
    Friesen EL; De Snoo ML; Rajendran L; Kalia LV; Kalia SK
    Parkinsons Dis; 2017; 2017():5015307. PubMed ID: 28913005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.